The Danish pharmaceutical company Lundbeck has experienced a decrease in sales in 2019, and it is to eat of the bottom line.
the Surplus has dropped by around 32 percent to 2.7 billion kroner. It shows the latest financial statements from Lundbeck, which is known for developing drugs against brain diseases.
the Decline in earnings is mainly due to a decrease in revenue of six percent to 17 billion crowns.
In the current year waiting Lundbeck a improved circulation, albeit the outbreak of the coronavirus in China creates uncertainty.
- China is Lundbeck's largest market, and the potential impact is difficult to quantify at the present time.
- Our financial expectation for the 2020 range, therefore, more widely than usually, write Lundbeck in its financial statements.
More specifically, the Lundbeck sales and produktdistribution in China, which is expected to be affected by the outbreak of the potentially deadly coronaviruses.
